BIOTIE THERAPIES INC has a total of 70 patent applications. It decreased the IP activity by 22.0%. Its first patent ever was published in 2008. It filed its patents most often in Australia, EPO (European Patent Office) and Japan. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are MUELLER-ENOCH DIETER, INNOVATIVE MED CONCEPTS LLC and SARIOLA HANNU.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 11 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | Japan | 6 | |
#4 | New Zealand | 6 | |
#5 | United States | 6 | |
#6 | Israel | 5 | |
#7 | WIPO (World Intellectual Property Organization) | 5 | |
#8 | Canada | 4 | |
#9 | China | 4 | |
#10 | Mexico | 4 | |
#11 | Hong Kong | 2 | |
#12 | Republic of Korea | 2 | |
#13 | Singapore | 2 | |
#14 | Argentina | 1 | |
#15 | Brazil | 1 | |
#16 | EAPO (Eurasian Patent Organization) | 1 | |
#17 | Philippines | 1 | |
#18 | Taiwan | 1 | |
#19 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Bandak Stephen I | 23 |
#2 | Moran Mark | 20 |
#3 | Pickford Lesley | 19 |
#4 | Malefyt Thomas R | 17 |
#5 | Black Kevin J | 17 |
#6 | Campbell Meghan C | 17 |
#7 | Woiwode Tom | 17 |
#8 | Salentine Christopher G | 14 |
#9 | Paborji Mehdi | 6 |
#10 | Tom Woiwode | 5 |
Publication | Filing date | Title |
---|---|---|
EP3518914A1 | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
AU2016208412A1 | Methods for treating dependence | |
US2018303843A1 | Controlled-release tozadenant formulations | |
AU2014202047A1 | Methods for treating dependence | |
WO2013181292A1 | Nitisinone formulations | |
NZ729564A | A2a antagonists as cognition and motor function enhancers | |
WO2012060844A1 | A2a antagonists as cognition and motor function enhancers | |
CA2742841A1 | Treatment of restless leg syndrome and sleep disorders | |
SG183696A1 | Medicaments comprising nepicastat for use in treating dependence on a substance | |
AU2008279169A1 | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |